TY  - JOUR
A1  - Adrián-Martínez, S.
A1  - Ageron, M.
A1  - Aharonian, F.
A1  - Aiello, S.
A1  - Albert, A.
A1  - Ameli, F.
A1  - Annasontzis, E.
A1  - Andre, M.
A1  - Androulakis, G.
A1  - Anghinolfi, M.
A1  - Anton, G.
A1  - Ardid, M.
A1  - Avgitas, T.
A1  - Barbarino, G.
A1  - Baret, B.
A1  - Barrios-Martí, J.
A1  - Belhorma, B.
A1  - Belias, A.
A1  - Berbee, A.
A1  - van den Berg, A.
A1  - Bertin, V.
A1  - Beurthey, S.
A1  - van Beeveren, V.
A1  - Beverini, N.
A1  - Biagi, S.
A1  - Biagioni, A.
A1  - Billault, M.
A1  - Bondì, M.
A1  - Bormuth, R.
A1  - Bouhadef, B.
A1  - Bourlis, G.
A1  - Bourret, S.
A1  - Boutonnet, C.
A1  - Bouwhuis, M.
A1  - Bozza, C.
A1  - Bruijn, R.
A1  - Brunner, J.
A1  - Buis, E.
A1  - Busto, J.
A1  - Cacopardo, G.
A1  - Caillat, L.
A1  - Calmai, M.
A1  - Calvo, D.
A1  - Capone, A.
A1  - Caramete, L.
A1  - Cecchini, S.
A1  - Celli, S.
A1  - Champion, C.
A1  - Cherkaoui El Moursli, R.
A1  - Cherubini, S.
A1  - Chiarusi, T.
A1  - Circella, M.
A1  - Classen, L.
A1  - Cocimano, R.
A1  - Coelho, J. A. B.
A1  - Coleiro, A.
A1  - Colonges, S.
A1  - Coniglione, R.
A1  - Cordelli, M.
A1  - Cosquer, A.
A1  - Coyle, P.
A1  - Creusot, A.
A1  - Cuttone, G.
A1  - D'Amico, A.
A1  - De Bonis, G.
A1  - De Rosa, G.
A1  - De Sio, C.
A1  - Di Capua, F.
A1  - Di Palma, I.
A1  - Díaz García, A. F.
A1  - Distefano, C.
A1  - Donzaud, C.
A1  - Dornic, D.
A1  - Dorosti-Hasankiadeh, Q.
A1  - Drakopoulou, E.
A1  - Drouhin, D.
A1  - Drury, L.
A1  - Durocher, M.
A1  - Eberl, T.
A1  - Eichie, S.
A1  - van Eijk, D.
A1  - El Bojaddaini, I.
A1  - El Khayati, N.
A1  - Elsaesser, D.
A1  - Enzenhöfer, A.
A1  - Fassi, F.
A1  - Favali, P.
A1  - Fermani, P.
A1  - Ferrara, G.
A1  - Filippidis, C.
A1  - Frascadore, G.
A1  - Fusco, L. A.
A1  - Gal, T.
A1  - Galatà, S.
A1  - Garufi, F.
A1  - Gay, P.
A1  - Gebyehu, M.
A1  - Giordano, V.
A1  - Gizani, N.
A1  - Gracia, R.
A1  - Graf, K.
A1  - Grégoire, T.
A1  - Grella, G.
A1  - Habel, R.
A1  - Hallmann, S.
A1  - van Haren, H.
A1  - Harissopulos, S.
A1  - Heid, T.
A1  - Heijboer, A.
A1  - Heine, E.
A1  - Henry, S.
A1  - Hernández-Rey, J. J.
A1  - Hevinga, M.
A1  - Hofestädt, J.
A1  - Hugon, C. M. F.
A1  - Illuminati, G.
A1  - James, C. W.
A1  - Jansweijer, P.
A1  - Jongen, M.
A1  - de Jong, M.
A1  - Kadler, M.
A1  - Kalekin, O.
A1  - Kappes, A.
A1  - Katz, U. F.
A1  - Keller, P.
A1  - Kieft, G.
A1  - Kießling, D.
A1  - Koffeman, E. N.
A1  - Kooijman, P.
A1  - Kouchner, A.
A1  - Kulikovskiy, V.
A1  - Lahmann, R.
A1  - Lamare, P.
A1  - Leisos, A.
A1  - Leonora, E.
A1  - Lindsey Clark, M.
A1  - Liolios, A.
A1  - Llorenz Alvarez, C. D.
A1  - Lo Presti, D.
A1  - Löhner, H.
A1  - Lonardo, A.
A1  - Lotze, M.
A1  - Loucatos, S.
A1  - Maccioni, E.
A1  - Mannheim, K.
A1  - Margiotta, A.
A1  - Marinelli, A.
A1  - Mariş, O.
A1  - Markou, C.
A1  - Martínez-Mora, J. A.
A1  - Martini, A.
A1  - Mele, R.
A1  - Melis, K. W.
A1  - Michael, T.
A1  - Migliozzi, P.
A1  - Migneco, E.
A1  - Mijakowski, P.
A1  - Miraglia, A.
A1  - Mollo, C. M.
A1  - Mongelli, M.
A1  - Morganti, M.
A1  - Moussa, A.
A1  - Musico, P.
A1  - Musumeci, M.
A1  - Navas, S.
A1  - Nicoleau, C. A.
A1  - Olcina, I.
A1  - Olivetto, C.
A1  - Orlando, A.
A1  - Papaikonomou, A.
A1  - Papaleo, R.
A1  - Păvălaş, G. E.
A1  - Peek, H.
A1  - Pellegrino, C.
A1  - Perrina, C.
A1  - Pfutzner, M.
A1  - Piattelli, P.
A1  - Pikounis, K.
A1  - Poma, G. E.
A1  - Popa, V.
A1  - Pradier, T.
A1  - Pratolongo, F.
A1  - Pühlhofer, G.
A1  - Pulvirenti, S.
A1  - Quinn, L.
A1  - Racca, C.
A1  - Raffaelli, F.
A1  - Randazzo, N.
A1  - Rapidis, P.
A1  - Razis, P.
A1  - Real, D.
A1  - Resvanis, L.
A1  - Reubelt, J.
A1  - Riccobene, G.
A1  - Rossi, C.
A1  - Rovelli, A.
A1  - Saldaña, M.
A1  - Salvadori, I.
A1  - Samtleben, D. F. E.
A1  - Sánchez García, A.
A1  - Sánchez Losa, A.
A1  - Sanguineti, M.
A1  - Santangelo, A.
A1  - Santonocito, D.
A1  - Sapienza, P.
A1  - Schimmel, F.
A1  - Schmelling, J.
A1  - Sciacca, V.
A1  - Sedita, M.
A1  - Seitz, T.
A1  - Sgura, I.
A1  - Simeone, F.
A1  - Siotis, I.
A1  - Sipala, V.
A1  - Spisso, B.
A1  - Spurio, M.
A1  - Stavropoulos, G.
A1  - Steijger, J.
A1  - Stellacci, S. M.
A1  - Stransky, D.
A1  - Taiuti, M.
A1  - Tayalati, Y.
A1  - Tézier, D.
A1  - Theraube, S.
A1  - Thompson, L.
A1  - Timmer, P.
A1  - Tönnis, C.
A1  - Trasatti, L.
A1  - Trovato, A.
A1  - Tsirigotis, A.
A1  - Tzamarias, S.
A1  - Tzamariudaki, E.
A1  - Vallage, B.
A1  - Van Elewyk, V.
A1  - Vermeulen, J.
A1  - Vicini, P.
A1  - Viola, S.
A1  - Vivolo, D.
A1  - Volkert, M.
A1  - Voulgaris, G.
A1  - Wiggers, L.
A1  - Wilms, J.
A1  - de Wolf, E.
A1  - Zachariadou, K.
A1  - Zornoza, J. D.
A1  - Zúñiga, J.
T1  - Letter of intent for KM3NeT 2.0
JF  - Journal of Physics G-Nuclear and Particle Physics
N2  - The main objectives of the KM3NeT Collaboration are (i) the discovery and subsequent observation of high-energy neutrino sources in the Universe and (ii) the determination of the mass hierarchy of neutrinos. These objectives are strongly motivated by two recent important discoveries, namely: (1) the high-energy astrophysical neutrino signal reported by IceCube and (2) the sizable contribution of electron neutrinos to the third neutrino mass eigenstate as reported by Daya Bay, Reno and others. To meet these objectives, the KM3NeT Collaboration plans to build a new Research Infrastructure consisting of a network of deep-sea neutrino telescopes in the Mediterranean Sea. A phased and distributed implementation is pursued which maximises the access to regional funds, the availability of human resources and the synergistic opportunities for the Earth and sea sciences community. Three suitable deep-sea sites are selected, namely off-shore Toulon (France), Capo Passero (Sicily, Italy) and Pylos (Peloponnese, Greece). The infrastructure will consist of three so-called building blocks. A building block comprises 115 strings, each string comprises 18 optical modules and each optical module comprises 31 photo-multiplier tubes. Each building block thus constitutes a three-dimensional array of photo sensors that can be used to detect the Cherenkov light produced by relativistic particles emerging from neutrino interactions. Two building blocks will be sparsely configured to fully explore the IceCube signal with similar instrumented volume, different methodology, improved resolution and
KW  - neutrino astronomy
KW  - eutrino physics
KW  - deep sea neutrino telescope
KW  - neutrino mass hierarchy
Y1  - 2016
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-188050
VL  - 43
IS  - 8
ER  - 
TY  - JOUR
A1  - Dekker, Annelot M.
A1  - Diekstra, Frank P.
A1  - Pulit, Sara L.
A1  - Tazelaar, Gijs H. P.
A1  - van der Spek, Rick A.
A1  - van Rheenen, Wouter
A1  - van Eijk, Kristel R.
A1  - Calvo, Andrea
A1  - Brunetti, Maura
A1  - Van Damme, Philip
A1  - Robberecht, Wim
A1  - Hardiman, Orla
A1  - McLaughlin, Russell
A1  - Chiò, Adriano
A1  - Sendtner, Michael
A1  - Ludolph, Albert C.
A1  - Weishaupt, Jochen H.
A1  - Pardina, Jesus S. Mora
A1  - van den Berg, Leonard H.
A1  - Veldink, Jan H.
T1  - Exome array analysis of rare and low frequency variants in amyotrophic lateral sclerosis
JF  - Scientific Reports
N2  - Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that affects 1 in ~350 individuals. Genetic association studies have established ALS as a multifactorial disease with heritability estimated at ~61%, and recent studies show a prominent role for rare variation in its genetic architecture. To identify rare variants associated with disease onset we performed exome array genotyping in 4,244 cases and 3,106 controls from European cohorts. In this largest exome-wide study of rare variants in ALS to date, we performed single-variant association testing, gene-based burden, and exome-wide individual set-unique burden (ISUB) testing to identify single or aggregated rare variation that modifies disease risk. In single-variant testing no variants reached exome-wide significance, likely due to limited statistical power. Gene-based burden testing of rare non-synonymous and loss-of-function variants showed NEK1 as the top associated gene. ISUB analysis did not show an increased exome-wide burden of deleterious variants in patients, possibly suggesting a more region-specific role for rare variation. Complete summary statistics are released publicly. This study did not implicate new risk loci, emphasizing the immediate need for future large-scale collaborations in ALS that will expand available sample sizes, increase genome coverage, and improve our ability to detect rare variants associated to ALS.
KW  - amyotrophic lateral sclerosis
KW  - genome-wide association studies
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-223686
VL  - 9
ER  - 
TY  - JOUR
A1  - Kittel-Schneider, Sarah
A1  - Felice, Ethel
A1  - Buhagiar, Rachel
A1  - Lambregtse-van den Berg, Mijke
A1  - Wilson, Claire A.
A1  - Banjac Baljak, Visnja
A1  - Vujovic, Katarina Savic
A1  - Medic, Branislava
A1  - Opankovic, Ana
A1  - Fonseca, Ana
A1  - Lupattelli, Angela
T1  - Treatment of peripartum depression with antidepressants and other psychotropic medications: a synthesis of clinical practice guidelines in Europe
JF  - International Journal of Environmental Research and Public Health
N2  - This study examined (1) the availability and content of national CPGs for treatment of peripartum depression, including comorbid anxiety, with antidepressants and other psychotropics across Europe and (2) antidepressant and other psychotropic utilization data as an indicator of prescribers' compliance to the guidelines. We conducted a search using Medline and the Guidelines International Network database, combined with direct e-mail contact with national Riseup-PPD COST ACTION members and researchers within psychiatry. Of the 48 European countries examined, we screened 41 records and included 14 of them for full-text evaluation. After exclusion of ineligible and duplicate records, we included 12 CPGs. Multiple CPGs recommend antidepressant initiation or continuation based on maternal disease severity, non-response to first-line non-pharmacological interventions, and after risk-benefit assessment. Advice on treatment of comorbid anxiety is largely missing or unspecific. Antidepressant dispensing data suggest general prescribers' compliance with the preferred substances of the CPG, although country-specific differences were noted. To conclude, there is an urgent need for harmonized, up-to-date CPGs for pharmacological management of peripartum depression and comorbid anxiety in Europe. The recommendations need to be informed by the latest available evidence so that healthcare providers and women can make informed, evidence-based decisions about treatment choices.
KW  - clinical practice guideline
KW  - depression
KW  - anxiety
KW  - antidepressant
KW  - psychotropic medications
KW  - peripartum
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-262130
SN  - 1660-4601
VL  - 19
IS  - 4
ER  -